Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Matching-adjusted indirect comparison of Isa-Kd versus Dara-Rd in relapsed multiple myeloma

Joshua Richter, MD, Mount Sinai Medical Center, New York City, NY, shares the findings from a matching-adjusted indirect comparison (MAIC) of isatuximab plus carfilzomib and dexamethasone (Isa-Kd) versus daratumumab plus lenalidomide and dexamethasone (Dara-Rd) in patients with relapsed/refractory (R/R) multiple myeloma. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Consultant/advisor: Janssen, BMS, Pfizer, Karyopharm, Sanofi, Takeda, Abbvie, Genentech
Speakers bureau: Janssen, BMS, Sanofi, Adaptive Biotechnologies